Tell Us Your Learning Needs
Thank you. You must be a healthcare professional in order to submit this form. If you have any questions, please contact our Medical Education team.

Major Depressive Disorder

On a scale of 1 to 4, please rate your current level of knowledge and interest in learning more about each of the following topics.*
Current Level of Knowledge       Desired Level of Knowledge
  

V-Low

 V-High    V-Low V-High
Challenges in MDD diagnosis: e.g. differential diagnosis (BP, ADHD, Borderline Personality etc.) 
  
Management of comorbidities in MDD (ADHD, Borderline Personality etc.)
  
Scales to establish a diagnosis and assess depression severity (e.g., HAM-D, PHQ-9, BDI, MADRS, etc.)
  
Initiation of antidepressant (AD) (choice of appropriate AD and differentiation between agents)
  
Specific features of MDD (e.g. anhedonia, low energy, emotional blunting)
  
Treatment Decisions (e.g., dose or medication adjustments, switch, adjunctive treatment) after initial assessment of early treatment response
  

What educational/learning formats/length do you prefer (select all that apply)?*
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Migraine

On a scale of 1 to 4, please rate your current level of knowledge and interest in learning more about each of the following topics.
Current Level of Knowledge       Desired Level of Knowledge
  

V-Low

 V-High    V-Low V-High
Clinical features of migraine and symptom recognition and Differentiation of migraine from other types of headache disorders
  
Neurobiology of migraine
  
Burden of migraine in patients from onset through recovery
  
Migraine and comorbidities-patient management
  
Mechanism(s) of action (MOA) of new and emerging preventive treatments
  
Safety and efficacy data from the clinical trials for CGRP receptor antagonists in the acute management of migraine
  
Evidence-based related to monoclonal antibody therapy and its relevance in the safe and effective use of antiCGRP monoclonal antibodies (mAbs) for migraine prevention
  

Safety and tolerability profile:

antiCGRP monoclonal antibodies

CGRP receptor antagonists
  

Adherence to long-term migraine preventative treatments
  

Switching between existing and emerging treatments
  

Combining antiCGRP-mAbs with other prophylactic medications
  

Updated guidelines on the management of migraine
  

Diagnosis and management of medication overuse headache
  

What educational/learning formats/length do you prefer (select all that apply)? 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

Schizophrenia

On a scale of 1 to 4, please rate your current level of knowledge and interest in learning more about each of the following topics.
Current Level of Knowledge       Desired Level of Knowledge
  

V-Low

 V-High    V-Low V-High
Most common challenges you experience when making the diagnosis of schizophrenia (such as: time required to complete diagnosis, differential diagnosis, assessing comorbidities [e.g., substance abuse], patient denial/reluctance)
  
Tools or resources that could further help you overcome any ongoing challenges
  
Discussion about inititiation of long-acting injectable (LAI) as a potential treatment option
  
In the inpatient setting, treatment considerations when initating treatment (such as: clinical experience, medication selection, efficacy and tolerability data, switch, initiation and adherence to treatment)
  
In the inpatient setting, challenges when initiating an atypical LAI (such as: clinical experience, medication selection, efficacy and tolerability data, switch, initiation and adherence to treatment)
  
In the outpatient setting, treatment considerations when initating treatment (such as: ongoing reduction of positive and negative symptoms, calming effect/reduction of agitation, long-term maintenance of efficacy and functioning, minimizing adverse events, HCP-patient shared decision making)
  
In the outpatient setting, challenges when initating oral treatment
  
In the outpatient setting, challenges when initiating an atypical LAIs (such as: clinical experience, medication selection, efficacy and tolerability data, switch, initiation and adherence to treatment)
  
Adding as needed (Pro re nata PRN) medications for patients who require short-term sedation when initiating antipsychotic treatment
  
Patient monitoring for ongoing treatment tolerability and maintenance of efficacy
  

What educational/learning formats/length do you prefer (select all that apply)? 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
* = Input is required
 
Select one from the list...